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Purpose of the study
The impact of HAART on health-related quality of life
(HRQoL) has been widely researched in the developed
world, however, there is limited data coming out of the
developing world and, in particular, sub-Saharan Africa,
where the vast majority of HIV-infected individuals live.
This study examined HRQoL among HIV-positive individ-
uals initiating HAART at the Hannan Crusaid Treatment
Centre in Gugulethu, Cape Town, and explored the
impact of HAART-related drug toxicities on HRQoL.
Methods
HRQoL was assessed using a standardised questionnaire,
the Medical Outcomes Survey Short Form 36 (MOS
SF36). Physical health summary (PHS) scores and mental
health summary (MHS) scores were compared pre-
HAART and at regular intervals during the first 48 weeks
of HAART. The impact of drug toxicities on HRQoL was
described and assessed both in unadjusted bivariate and
adjusted multivariate analyses.
Summary of results
This study reported a significant increase in HRQoL dur-
ing the first 48 weeks on HAART with the bulk of this
increase occurring during the first 16 weeks. Although
there was a general improvement in HRQoL on HAART,
23% of participants reported a decline in PHS score, and
34% a decline in MHS score. Average drops in median
PHS and MHS scores were 8.4 units (SD 9.31) and 9.9
units (SD 11.4), respectively. Eleven (4%) participants
reported drug toxicity. Most toxicities (63%) occurred
between weeks 32 and 48, and 73% were related to stavu-
dine. Participants who experienced drug toxicity reported
lower PHS scores than participants without a drug toxicity
at all time points. However, only 27% (three) of partici-
pants with drug toxicity reported a decline in HRQoL
between pre-HAART and week 48. Drug toxicities had lit-
tle impact on MHS scores.
Conclusion
This study confirmed the HRQoL benefits of HAART in a
community ARV clinic in South Africa. While the majority
of patients experienced a significant improvement in
HRQoL on HAART, up to a third of patients reported
declines in HRQoL. HAART-related drug toxicities
(including those secondary to the use of stavudine) did
not have a significant negative impact on HRQoL during
the first 48 weeks of HAART supporting the ongoing use
of stavudine in the national ARV roll-out programme.
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